Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24115646 | 0.94 | NPC1 (0.41) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL18866930 | 0.85 | NPC1 (0.39) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL2706284 | 0.78 | NPC1 (0.50) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL12938128 | 0.78 | NPC1 (0.50) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL19841674 | 0.77 | NPC1 (0.34) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL20880273 | 0.76 | NQO2 (0.43) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23739009 | 0.76 | NQO2 (0.43) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16639705 | 0.74 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18855039 | 0.74 | RAB9A (0.41) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL19841535 | 0.73 | NPC1 (0.41) | NPC1RAB9ASCN4ASMN1; SMN2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | SORRENTO THERAPEUTICS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | NPC1 330/4885RAB9A 764/4885SCN4A 4641/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | NPC1 330/4885RAB9A 764/4885SCN4A 4641/4885 |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | CD274, CD47, CD22 | NPC1 3711/4885RAB9A 3098/4885SCN4A 4323/4885 |
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | PAICS, CES2, DNPEP | NPC1 635/4885RAB9A 1067/4885SCN4A 4702/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | NPC1 635/4885RAB9A 1067/4885SCN4A 4702/4885 |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | ERBB2, ABCG2, DYNLL2 | NPC1 2589/4885RAB9A 627/4885SCN4A 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.